F2 and venous thromboembolism: The aim of this study was to assess the impact of genetic risk factors including prothrombin 20210, Factor V Leiden, plasminogen activator inhibitor 4G/5G, and Factor XIII V34L on the occurrence of venous thromboembolism in patients.